Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand

Agreement expands Mycovia’s international commercialization plans for VT-1161 to European countries, Latin America, Australia, Russia and Commonwealth of Independent States

Mycovia will continue to quickly develop VT-1161 as a prospective first FDA-approved remedy for recurrent vulvovaginal candidiasis

DURHAM, N.C.–( COMPANY WIRE )–Mycovia Pharmaceuticals, Inc. today announced this has entered into a unique permit and development and technology transfer contract with Gedeon Richter Plc., situated in Budapest, Hungary, to commercialize and produce VT-1161 in European countries, Latin America, Australia, Russia along with other CIS nations. VT-1161, a dental antifungal item prospect, happens to be in stage 3 medical studies for the remedy for Recurrent Vulvovaginal Candidiasis (RVVC), a debilitating, chronic infectious condition that impacts almost 138 million ladies global every year.

“We are excited to partner with Gedeon Richter, a business with strong market leadership in women’s health, to produce and commercialize VT-1161, our prospective first treatment that is FDA-approved RVVC,” said Patrick Jordan, CEO of Mycovia and Partner at NovaQuest Capital Management, which formed Mycovia in 2018 to advance VT-1161 in worldwide areas. “VT-1161 is well positioned to handle the needs of the an incredible number of ladies who have problems with vexation, pain and psychological distress due to RVVC and so are searching for a treatment option that is new. We anticipate formalizing our commercial strategy and launch plans even as we quickly advance VT-1161 through the hospital and prepare our submission that is regulatory.

VT-1161 was created to be extremely selective, with fewer negative effects and efficacy that is improved present treatment plans. Mycovia happens to be performing phase that is global studies of VT-1161 in women with RVVC to guide advertising applications into the U.S., europe and Japan. Continue reading “Mycovia Pharmaceuticals Announces Partnership with Gedeon Richter to Commercialize and Manufacture VT-1161 for Recurrent Vulvovaginal Cand”